ClinicalTrials.gg
CompletedNCT05158777Updated Dec 29, 2023

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

A Phase 3 interventional study of Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd. and Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd in Varicella, sponsored by Shanghai Institute Of Biological Products. Completed at 1 site in China. Open to participants aged 13 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-29.

Sponsored by Shanghai Institute Of Biological Products (part of Sinopharm) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,480
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Chickenpox with a site in China — 7 open to participants now, 12 under way, 4 of them phase 3. Chickenpox · China.

Enrollment
7th of 31
2,480 · median 899
Started
2022
with 3 others
Phase 3
9 of 31
2 open now
Registered
14th of 31
by date
Lead sponsor
1 of 31
Shanghai Institute Of Biological Products

Among the 31 studies in Chickenpox with a site in China, this one is the 7th largest by enrollment, is one of 4 that started in 2022, is one of 9 in phase 3, and was the 14th registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

7 of the 31 studies in Chickenpox with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 13 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Chickenpox with a site in China, or all of them as a file.
02

Study summary

This is a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd. The purpose of this study is to evaluate the immunogenicity and safety of a two doses vaccination of investigational vaccine with 0,28 day and 0,56 day immunization schedule in population aged ≥13 years old.

Read the detailed description

This study is a randomized, blind, controlled phase III clinical trial in population aged ≥13 years old. The experimental vaccine will be manufactured by Shanghai Institute of Biological Products Co.,Ltd.. A total of 2480 subjects aged 13 years and older will be enrolled with 1240 subjects in 13\~17 years old group and1240 subjects in 18 years and older group. 1240 subjects in each age group would be randomly divided into experimental group and control group according to 1:1 ratio, and subjects will receive two doses of vaccine with the immunization course of 0,28 days or 0,56 days. In addition, 400 subjects from experimental group (100 subjects per subgroup) would be selected to collect blood at 3 and 5 years after immunization to evaluate immune persistence of live attenuated varicella vaccines.

03

Conditions studied

  • Varicella

Browse trials for

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy population aged 13 years and above;
  • Proven legal identity;
  • The subjects and/or guardians can understand and voluntarily sign the form (For subjects aged 13-17 years, both subjects and guardians need to sign the informed consent form).

Exclusion criteria

Exclusion Criteria:

  • Disease history or vaccine history of chickenpox or shingles;
  • Have fever before vaccination, axillary temperature >37.0°C;
  • Already pregnant (including a positive urine pregnancy test) or are breastfeeding, planning to get pregnant within 6 months;
  • History of severe allergy and asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema and abdominal pain;
  • Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
  • disease or immunodeficiency / ;
  • Severe chronic diseases, severe cardiovascular diseases, hypertension (adult field measurement: SBP ≥140mmHg or diastolic blood pressure ≥90mmHg) that could not be controlled by drugs, diabetes, liver and kidney diseases, malignant tumors, etc.;
  • Family history of psychosis,severe neurological disease (epilepsy, convulsions or twitching) or mental illness;
  • Thyroid disease or history of thyroidectomy, asplenia, functional asplenia, asplenia or splenectomy resulting from any condition;
  • Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal ) or obvious bruising or blood coagulation;
  • Immunosuppressive therapy, cytotoxic therapy, inhaled (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
  • History of alcohol or drug abuse;
  • Receipt of blood products within in the past 6 months;
  • Participating in other drug/vaccine clinical trial;
  • Receipt of attenuated in the past 28 days;
  • Receipt of inactivated or subunit vaccines in the past 7 days;
  • Onset of various acute or chronic diseases within 7 days prior to the study;
  • According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,480 participants (actual)

Study arms

  • Experimental
    Experimental Group with the immunization course of 0,28 days or 0,56 days

    1240 subjects (including 620 children aged 13-17 years and 620 adults aged 18 years and older) will receive two doses of experimental vaccine with the immunization course of 0,28 days or 0,56 days.

    Biological: Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.

  • Active comparator
    Control Group

    1240 subjects (including 620 children aged 13-17 years and 620 adults aged 18 years and older) will receive two doses of control vaccine with the immunization course of 0,28 days or 0,56 days.

    Biological: Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd

Interventions

  • BiologicalLive attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.

    live varicella-zoster virus in 0.5 mL of sucrose, sodium chloride, potassium chloride, sodium glutamate, phosphate and injection water per injection

  • BiologicalLive attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd

    live varicella-zoster virus in 0.5 mL of mannitol, dextrose tincture, sucrose, trehalose, human serum albumin and injection water per injection

06

What researchers measure

Primary outcomes

  1. Seroconversion rate of HI antibody

    The seroconversion rate of the antibody 42 days among all subjects after the second vaccination.

    Time frame: Day 42 after the whole schedule

  2. GMT of HI antibody

    The GMT of the antibody 42 days among all subjects after the second vaccination.

    Time frame: Day 42 after the whole schedule

Secondary outcomes

  1. Seroprotection rate of HI antibody

    The seroprotection rate of the antibody 42 days among all subjects after the second vaccination.

    Time frame: Day 42 after the whole schedule

  2. Incidence of adverse reactions within 30 minutes after each dose

    Incidence of adverse reactions within 30 minutes after each dose vaccination with immunization course of 0,28 days and 0,56 days.

    Time frame: Within 30 minutes after each dose

  3. Incidence of adverse reactions within 0~28 days after each dose

    Incidence of adverse reactions within 0\~28 days after each dose vaccination with immunization course of 0,28 days and 0,56 days.

    Time frame: Within 0~28 days after each dose

  4. Incidence of serious adverse events

    Incidence of serious adverse events from vaccination to 6 months after the second vaccination with immunization course of 0,28 days and 0,56 days

    Time frame: From vaccination to 6 months after the second vaccination

07

Study locations

1 site
  • Henan Provincial Center for Disease Prevention and Control
    Zhenzhou, Henan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Nov 2022, 9 months.

Of 35 industry-sponsored phase 3 interventional studies under Chickenpox, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 15. This study's 9 months is below that.

Counting every sponsor, half of 39 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2021
First posted
Dec 15, 2021
StartActual
Feb 13, 2022
Primary completionActual
Nov 14, 2022
CompletionActual
Nov 14, 2022
Last update
Dec 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05158777
Responsible party
Sponsor
First posted
Dec 15, 2021
Start date
Feb 13, 2022
Primary completion
Nov 14, 2022
Completion
Nov 14, 2022
Last update
Dec 29, 2023

Study contacts

Yanxia Wang
principal investigator · Henan Provincial Center for Disease Control and Prevention

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion